Register for our free email digests:
Division of TiGenix NV
Latest From Albany Molecular Research Inc.
Novartis will invest in the Calgary-based Parvus and collaborate on a Navacim candidate for type 1 diabetes. Japan's Sawai moves into the US market by acquiring Upsher-Smith's generics business, while Denovo acquires a suspended depression candidate from AMRI for its personalized development approach.
EnteroMedics appoints president and CEO; former Medtronic chair elected to Halyard Health Board of Directors; T2 Biosystems names chief commercial officer; AngioDynamics CFO transition; new Merit Medical Systems CFO tapped.
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
- Gene Therapy, Cell Therapy
- Therapeutic Areas
- Immune Disorders
- Musculoskeletal & Connective Tissue Disorders
- Western Europe
- Parent & Subsidiaries
- TiGenix NV
- Senior Management
Eduardo Bravo, CEO
Claudia D'Augusta, PhD, CFO
Jose Luis Bravo, MD, PhD, VP, Global Medical, R&D
- Contact Info
Phone: (34) 91 804 92 64
Calle Marconi, 1
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.